Darema M, Cholongitas E, Filiopoulos V, et al. - Given the very good safety and efficacy profiles of recent interferon-free direct-acting antiviral (DAA) regimens, researchers here investigated the safety and efficacy of these regimens in kidney transplant (KT) recipients with chronic hepatitis C (CHC). They retrospectively evaluated 12 KT recipients who received therapy with the current DAAs. Among these cases, 2 had received antiviral therapy in the past; 4 (33.3%) patients had genotype 1 and 3 (25%) genotype 4 CHC. A sustained virological response (SVR) was achieved in 11 (91.7%) patients. DAAs were discontinued early after treatment by one patient who did not achieve SVR. This real-world study confirmed DAAs as highly efficacious and clinically acceptable regimens for KT recipients with CHC.